Fixed-Dose Netupitant and Palonosetron for Chronic Nausea and Vomiting in Cancer Patients
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Netupitant/palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 28 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 16 Jul 2019 Planned number of patients changed from 50 to 60.
- 02 Jul 2019 Planned End Date changed from 1 May 2019 to 30 Nov 2019.